Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective

Thomas S. C. Ng; Xin Gao; Keyan Salari; Dimitar V. Zlatev; Pedram Heidari; Sophia C. Kamran

doi:10.3389/fonc.2021.722277

Frontiers in Oncology (Jul 2021)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective

Thomas S. C. Ng,
Xin Gao,
Keyan Salari,
Dimitar V. Zlatev,
Pedram Heidari,
Sophia C. Kamran

Affiliations

Thomas S. C. Ng: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Xin Gao: Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Keyan Salari: Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Dimitar V. Zlatev: Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Pedram Heidari: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Sophia C. Kamran: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

DOI: https://doi.org/10.3389/fonc.2021.722277
Journal volume & issue: Vol. 11

Abstract

Read online

Recent developments in prostate-specific membrane antigen (PSMA) targeted diagnostic imaging and therapeutics (theranostics) promise to advance the management of primary, biochemically recurrent, and metastatic prostate cancer. In order to maximize the clinical impact of PSMA-targeted theranostics, a coordinated approach between the clinical stakeholders involved in prostate cancer management is required. Here, we present a vision for multidisciplinary use of PSMA theranostics from the viewpoints of nuclear radiology, medical oncology, urology, and radiation oncology. We review the currently available and forthcoming PSMA-based imaging and therapeutics and examine current and potential impacts on prostate cancer management from early localized disease to advanced treatment-refractory disease. Finally, we highlight the clinical and research opportunities related to PSMA-targeted theranostics and describe the importance of multidisciplinary collaboration in this space.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords